The efficacy and safety of biologic response modifiers such as etanercept, adalimumab, infliximab, and ustekinumab have been demonstrated in the treatment of psoriasis in adults, but none are currently approved for the treatment of psoriasis in children in the United States, and only etanercept is approved for the treatment of psoriasis in children in the European Union. Through case reports, case series, and a large clinical trial of the use of etanercept, the literature supports the use of these agents to treat psoriasis in children. Data on the use of the tumor necrosis factor-α antagonists etanercept, adalimumab, and infliximab in the treatment of other inflammatory diseases in children-namely Crohn's disease, juvenile arthritis, and uveitis--support their safety profile in children.
The novel coronavirus SARS-CoV-2 has been associated with a variety of dermatologic manifestations, often the predominant finding in otherwise asymptomatic or oligosymptomatic patients. Urticarial eruption is one example, but few cases have been reported among pediatric patients. We present a case of acute urticaria in a 6-month-old boy preceding other COVID-19 symptoms. The suspicion of a possible COVID-19-associated cutaneous manifestation prompted timely testing and diagnosis of SARS-CoV-2 infection.
Background/Objectives
Differences in appearance are often stigmatized in society, and dermatologic disease can lead to psychological and social sequelae that significantly impact patient quality of life. However, discrepancy between patient‐reported and physician‐assessed psychological distress raises a question of how clinicians are prepared in recognizing and managing the psychosocial impact of a child's skin condition. We aim to identify current practices among healthcare providers toward properly addressing appearance‐related psychosocial distress in pediatric dermatology patients.
Methods
Surveys assessing provider attitude and practices to appearance‐related distress were distributed to members of the Society of Pediatric Dermatology via the Pediatric Dermatology Research Alliance, and Florida Chapter of American Academy of Pediatrics.
Results
Over half of respondents report encountering appearance‐related psychosocial distress on a daily basis and believe screening to be important. However, only 14% use a validated screening tool and 18% screen all patients. Major obstacles to generalized screening were limited time and staffing. Self‐reported knowledge and management of appearance‐related psychosocial distress includes direct counseling and referrals to local support groups, mental health providers, specialized summer camps, and school‐affiliated resources. Nevertheless, 86% expressed interest in learning more about appearance‐related psychosocial distress, particularly about patient education and resources.
Conclusions
Although clinicians frequently encounter appearance‐related distress with pediatric dermatology patients, screening is selective and lacks standardization. Self‐reported knowledge and management is comprehensive, but there is a need for increased training in patient education and resources.
The role of early dietary modification for possible prevention of atopic dermatitis (AD) in the at-risk infant remains ambiguous to caregivers and physicians alike. The popular association made by patients or caregivers between the development and/or aggravation of atopic dermatitis due to food hypersensitivity may lead to unmonitored and unwarranted dietary exclusion, which can lead to malnutrition, growth stunting, vitamin deficiencies and even kwashiorkor. 1,2 Thus, it is of great importance for the dermatologist to be able to provide evidence-based recommendations to caregivers of infants at high risk (ie positive family history for allergic diseases such as asthma, allergic rhinitis or atopic dermatitis) for AD. The purpose of this review was to examine the role of AD prevention
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.